Prognostic utility of pre-biologic treatment correlates of childhood severe asthma exacerbation risk: Real world evidence.

ABSTRACT:

Background

Biologics have been shown to substantially reduce the risk of severe asthma exacerbations (SAEs) among children with moderate or severe asthma; however, not all eligible patients who initiate biologic treatment experience a reduced risk of SAEs.

Methods

Using a longitudinal study design, we analyzed data from 122 children with moderate/severe asthma treated with a biologic by pediatric subspecialists between December 2019 and December 2024. We used logistic and Cox proportional hazards models to identify and quantify the prognostic utility of clinical correlates of increased SAE risk among children with moderate or severe asthma prior to biologic treatment initiation.

Results

Biologic agents (dupilumab, omalizumab, and mepolizumab) had differential effects

SUBMITTER: Owora AH 

PROVIDER: S-EPMC12673514 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature